Hookipa Pharma INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
10-Q: HOOKIPA Pharma Reports Q1 2025 Results: Revenue Declines Amid Strategic Shift and Restructuring
HOOKIPA Pharma's Q1 2025 revenue decreased significantly due to the termination of the Roche collaboration, while the company focuses on strategic alternatives and cost-saving measures.
OTC.Pink
HOOKIPA Pharma's Q3 2024 results reflect a strategic refocus, restructuring efforts, and continued development of its immuno-oncology pipeline, with a net loss of $13.8 million.
OTC.Pink
HOOKIPA Pharma Inc. announced its second quarter 2024 results, highlighting a strategic shift towards its oncology programs and a restructuring plan.
OTC.Pink
10-Q: HOOKIPA Pharma Reports Q1 2024 Results, Driven by Collaboration Revenue and Strategic Restructuring
HOOKIPA Pharma's Q1 2024 results show a significant increase in revenue due to collaboration agreements and a strategic restructuring to focus on key programs.